This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Andreas Hougaard Laustsen-Kiel, Ph.D.
Professor, Tropical Pharmacology & Biotherapeutics at Technical University of Denmark


Professor Andreas Hougaard Laustsen-Kiel heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine at the Technical University of Denmark and is specialized in antibody technologies. He is also the CTO of Bactolife ApS, responsible for nanobody technology and discovery in this company. Andreas is a Fellow of the Danish Academy of Technical Sciences, the Young Academy of Denmark, and the Young Academy of Europe. He holds a PhD from the University of Copenhagen and an M.Sc.Eng. from DTU. Andreas is a co-founder of Biosyntia, VenomAb, Antag Therapeutics, Chromologics, VenomAid Diagnostics, and Bactolife and is recognized as Denmark’s Coolest Engineer (Engineer The Future), was listed on Forbes 30 under 30 in 2017, and was a Top 35 Innovator under 35 by MIT Technology Review 2017. Combined, Andreas has been (co-)responsible for securing USD 85+ million for his research and ventures, and has published 60+ peer reviewed articles.

Agenda Sessions

  • Recombinant Antivenom Based on Oligoclonal Broadly-neutralizing Antibodies